Telomir signs binding LOI to acquire TELI, consolidating worldwide rights to Telomir-1

Telomir Pharmaceuticals, Inc.

• Acquires all TELI shares via stock-for-stock exchange; exchange ratio based on third-party valuation.
• Certain TELI shareholders to contribute $5M cash: $1M at closing, $2M on FDA IND acceptance, $2M on Phase 1/2 start.
• Transaction consolidates global IP rights to Telomir-1, an oral epigenetic therapy for cancer and aging.
• No TELI leadership retained post-closing; TELI shareholders subject to six-month lock-up.
• Closing subject to due diligence, board/stockholder approvals, regulatory clearances within 90 days.